Arne Koscielny1, Anna Ko2, Eva K Egger3, Walter Kuhn4, Jörg C Kalff2, Mignon-Denise Keyver-Paik3. 1. Department of Surgery, University of Bonn Medical School, Bonn, Germany Arne.Koscielny@ukb.uni-bonn.de. 2. Department of Surgery, University of Bonn Medical School, Bonn, Germany. 3. Department of Gynecologic Oncology, University of Bonn Medical School, Bonn, Germany. 4. Department of Gynecology and Obstetrics, Donau-Isar-Klinikum, Deggendorf, Germany.
Abstract
AIM: The aim of this retrospective study was to investigate the impact of anastomotic leakage on survival rate and to define potential factors of risk and protection from bowel anastomotic leakage in patients with bowel segment resection treated for epithelial ovarian cancer in an accredited high-volume center. PATIENTS AND METHODS: Data of 136 patients treated with bowel resection between 2010 and 2017 were collected. All operations were performed by three accredited gynecological oncologists and by two specialized colorectal surgeons. Survival and anastomotic leakage rates were analyzed as per preoperative treatment, number and localization of anastomoses, grading of ovarian cancer, and protective loop ileostomy. RESULTS: In total, anastomotic leakage was observed in 23 out of 165 anastomoses (13.9%), representing 23 anastomotic leakages in 136 patients (16.9%). The 30-day mortality rate was 0.73%. There was no statistically significant difference in anastomotic leakage rate depending on localization and number of anastomoses (p=0.634). Patients with a protective loop ileostomy (n=22/136 patients) had no anastomotic leakage (0.0%, p=0.021). The anastomotic leakage rate was significantly different in patients without protective loop ileostomy depending on bevacizumab administration [no bevacizumab: 15/111 (13.5%) vs. bevacizumab administration: 4/8 (50.0%), p=0.007]. Tumor-positive resection margins in bowel segments were an independent prognostic factor (relative risk=6.3; 95% confidence intervaI=3.1-12.9). CONCLUSION: In this data set, protective loop ileostomy likely reduced the anastomotic leakage rate after bowel resection in selected cases of ovarian cancer treated with debulking surgery. Especially in patients treated with bevacizumab, protective loop ileostomy should be considered. There was no significant impact of leakage rate on overall survival. Copyright
AIM: The aim of this retrospective study was to investigate the impact of anastomotic leakage on survival rate and to define potential factors of risk and protection from bowel anastomotic leakage in patients with bowel segment resection treated for epithelial ovarian cancer in an accredited high-volume center. PATIENTS AND METHODS: Data of 136 patients treated with bowel resection between 2010 and 2017 were collected. All operations were performed by three accredited gynecological oncologists and by two specialized colorectal surgeons. Survival and anastomotic leakage rates were analyzed as per preoperative treatment, number and localization of anastomoses, grading of ovarian cancer, and protective loop ileostomy. RESULTS: In total, anastomotic leakage was observed in 23 out of 165 anastomoses (13.9%), representing 23 anastomotic leakages in 136 patients (16.9%). The 30-day mortality rate was 0.73%. There was no statistically significant difference in anastomotic leakage rate depending on localization and number of anastomoses (p=0.634). Patients with a protective loop ileostomy (n=22/136 patients) had no anastomotic leakage (0.0%, p=0.021). The anastomotic leakage rate was significantly different in patients without protective loop ileostomy depending on bevacizumab administration [no bevacizumab: 15/111 (13.5%) vs. bevacizumab administration: 4/8 (50.0%), p=0.007]. Tumor-positive resection margins in bowel segments were an independent prognostic factor (relative risk=6.3; 95% confidence intervaI=3.1-12.9). CONCLUSION: In this data set, protective loop ileostomy likely reduced the anastomotic leakage rate after bowel resection in selected cases of ovarian cancer treated with debulking surgery. Especially in patients treated with bevacizumab, protective loop ileostomy should be considered. There was no significant impact of leakage rate on overall survival. Copyright
Authors: Eva Katharina Egger; Natascha Kohls; Matthias B Stope; Mateja Condic; Mignon-Denise Keyver-Paik; Dominique KÖnsgen; Tobias Hilbert; Sven Klaschik; Daniel Exner; Tim Vilz; Alexander Mustea Journal: In Vivo Date: 2020 Nov-Dec Impact factor: 2.155
Authors: Barbara Costantini; Virginia Vargiu; Francesco Santullo; Andrea Rosati; Matteo Bruno; Valerio Gallotta; Claudio Lodoli; Rossana Moroni; Fabio Pacelli; Giovanni Scambia; Anna Fagotti Journal: Ann Surg Oncol Date: 2022-04-18 Impact factor: 4.339
Authors: Antoni Llueca; Anna Serra; Maria Teresa Climent; Karina Maiocchi; Alvaro Villarin; Katty Delgado; Josep Mari-Alexandre; Juan Gilabert-Estelles; Paula Carrasco; Blanca Segarra; Luis Gomez; Juan Jose Hidalgo; Javier Escrig; Manuel Laguna Journal: Cancer Manag Res Date: 2021-01-06 Impact factor: 3.989
Authors: Eva K Egger; Freya Merker; Damian J Ralser; Milka Marinova; Tim O Vilz; Hanno Matthaei; Tobias Hilbert; Alexander Mustea Journal: Front Surg Date: 2022-08-24